United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

casen recordati s.l. - sodium picosulfate; citric acid monohydrate; magnesium oxide light - oral powder - 10mg ; 12gram ; 3.5gram

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmaco (nz) ltd - citric acid monohydrate 12 g; light magnesium oxide 3.5 g; sodium picosulfate 5mg - powder for oral solution - active: citric acid monohydrate 12 g light magnesium oxide 3.5 g sodium picosulfate 5mg excipient: orange flavour 655280 potassium bicarbonate saccharin sodium

United States - English - NLM (National Library of Medicine)

camber pharmaceuticals, inc. - sodium picosulfate (unii: lr57574hn8) (deacetylbisacodyl - unii:r09078e41y), magnesium oxide (unii: 3a3u0gi71g) (magnesium cation - unii:t6v3lhy838), anhydrous citric acid (unii: xf417d3psl) (anhydrous citric acid - unii:xf417d3psl) - sodium picosulfate, magnesium oxide and anhydrous citric acid for oral solution is indicated for cleansing of the colon as a preparation for colonoscopy in adults and pediatric patients 9 years of age and older. sodium picosulfate, magnesium oxide and anhydrous citric acid for oral solution is contraindicated in the following conditions: • patients with severe renal impairment (creatinine clearance less than 30 ml/minute) which may result in accumulation of magnesium  [see warnings and precautions ( 5.4)] • gastrointestinal obstruction or ileus [see warnings and precautions ( 5.6)] • bowel perforation [see warnings and precautions ( 5.6)] • toxic colitis or toxic megacolon • gastric retention • hypersensitivity to any of the ingredients in sodium picosulfate, magnesium oxide and anhydrous citric acid for oral solution  [see advers

United States - English - NLM (National Library of Medicine)

navajo manufacturing company inc. - citric acid monohydrate (unii: 2968phw8qp) (anhydrous citric acid - unii:xf417d3psl), sodium bicarbonate (unii: 8mdf5v39qo) (sodium cation - unii:lyr4m0nh37) - anhydrous citric acid 1.9485 g - for the relief of: • heartburn • sour stomach • acid indigestion • upset stomach associated with these symptoms

United States - English - NLM (National Library of Medicine)

reckitt benckiser mexico, s.a. de c.v. - citric acid monohydrate (unii: 2968phw8qp) (anhydrous citric acid - unii:xf417d3psl), sodium bicarbonate (unii: 8mdf5v39qo) (sodium cation - unii:lyr4m0nh37, bicarbonate ion - unii:hn1zra3q20) - anhydrous citric acid 1.9485 g - for the relief of - heartburn - sour stomach - acid indigestion - upset stomach associated with these symptoms

United States - English - NLM (National Library of Medicine)

bayer healthcare llc. - citric acid monohydrate (unii: 2968phw8qp) (anhydrous citric acid - unii:xf417d3psl), sodium bicarbonate (unii: 8mdf5v39qo) (sodium cation - unii:lyr4m0nh37) - anhydrous citric acid 1000 mg - active ingredients (in each tablet)...................................................................................purpose anhydrous citric acid 1000 mg....................................................................................... antacid sodium bicarbonate (heat-treated) 1940 mg ..............................................................antacid for the relief of - heartburn - acid indigestion - upset stomach associated with these symptoms

United States - English - NLM (National Library of Medicine)

ferring pharmaceuticals inc. - sodium picosulfate (unii: lr57574hn8) (deacetylbisacodyl - unii:r09078e41y), magnesium oxide (unii: 3a3u0gi71g) (magnesium cation - unii:t6v3lhy838), anhydrous citric acid (unii: xf417d3psl) (anhydrous citric acid - unii:xf417d3psl) - sodium picosulfate 10 mg in 16.1 g - prepopik® is indicated for cleansing of the colon as a preparation for colonoscopy in adults and pediatric patients 9 years of age and older. prepopik is contraindicated in the following conditions: - patients with severe renal impairment (creatinine clearance less than 30 ml/minute) which may result in accumulation of magnesium [see warnings and precautions (5.4)] - gastrointestinal obstruction or ileus [see warnings and precautions (5.6)] - bowel perforation [see warnings and precautions (5.6)] - toxic colitis or toxic megacolon - gastric retention - hypersensitivity to any of the ingredients in prepopik [see adverse reactions (6.2)] risk summary there are no data with prepopik use in pregnant women to determine a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. in an animal reproduction study, no adverse developmental effects were observed in pregnant rats when sodium picosulfate, magnesium oxide, and anhydrous citric acid were administered orally at doses 1

United States - English - NLM (National Library of Medicine)

ferring pharmaceuticals inc. - sodium picosulfate (unii: lr57574hn8) (deacetylbisacodyl - unii:r09078e41y), magnesium oxide (unii: 3a3u0gi71g) (magnesium cation - unii:t6v3lhy838), anhydrous citric acid (unii: xf417d3psl) (anhydrous citric acid - unii:xf417d3psl) - sodium picosulfate 10 mg in 160 ml - clenpiq is indicated for cleansing of the colon as a preparation for colonoscopy in adults and pediatric patients 9 years of age and older. clenpiq is contraindicated in the following conditions: - patients with severe renal impairment (creatinine clearance less than 30 ml/minute), which may result in accumulation of magnesium [see warnings and precautions (5.3)]. - gastrointestinal obstruction or ileus [see warnings and precautions (5.6)]. - bowel perforation [see warnings and precautions (5.6)]. - toxic colitis or toxic megacolon. - gastric retention. - hypersensitivity to any of the ingredients in clenpiq [see adverse reactions (6.2)]. risk summary there are no data with clenpiq use in pregnant women to determine a drug-associated risk of adverse developmental outcomes. in animal reproduction studies, no adverse developmental effects were observed in pregnant rats when sodium picosulfate, magnesium oxide, and anhydrous citric acid were administered orally at doses 1.2 times the recommended human dose based

United States - English - NLM (National Library of Medicine)

haemonetics corporation - citric acid monohydrate (unii: 2968phw8qp) (anhydrous citric acid - unii:xf417d3psl), trisodium citrate dihydrate (unii: b22547b95k) (anhydrous citric acid - unii:xf417d3psl), sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (phosphate ion - unii:nk08v8k8hr), anhydrous dextrose (unii: 5sl0g7r0ok) (anhydrous dextrose - unii:5sl0g7r0ok) - anhydrous citric acid 32.7 mg in 1 ml - for use with haemonetics apheresis devices rx only the haemonetics 250ml anticoagulant citrate phosphate double dextrose (cp2d) and 250ml additive solution formula 3 (as-3) nutrient solution are intended to be used only with automated apheresis devices for collecting human blood and blood components. the anticoagulant solution is metered by the apheresis machine into the collected whole blood. it is not to be infused directly into the donor. after the anticoagulant is used, the bag in which it was contained is discarded. when collecting plasma in the rbcp protocol, the plasma is collected into an empty plasma collection bag. one hundred milliliters (100ml) of as-3 is transferred into one rbc collection bag when using the rbcp protocol or 2 separate bags when using the

United States - English - NLM (National Library of Medicine)

haemonetics corporation - citric acid monohydrate (unii: 2968phw8qp) (anhydrous citric acid - unii:xf417d3psl), sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (phosphate ion - unii:nk08v8k8hr), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), adenine (unii: jac85a2161) (adenine - unii:jac85a2161), anhydrous dextrose (unii: 5sl0g7r0ok) (anhydrous dextrose - unii:5sl0g7r0ok), trisodium citrate dihydrate (unii: b22547b95k) (anhydrous citric acid - unii:xf417d3psl) - anhydrous citric acid 4.2 mg in 1 ml - the haemonetics 250ml anticoagulant citrate phosphate double dextrose (cp2d) and 250ml additive solution formula 3 (as-3) nutrient solution are intended to be used only with automated apheresis devices for collecting human blood and blood components. the anticoagulant solution is metered by the apheresis machine into the collected whole blood. it is not to be infused directly into the donor. after the anticoagulant is used, the bag in which it was contained is discarded. when collecting plasma in the rbcp protocol, the plasma is collected into an empty plasma collection bag. one hundred milliliters (100ml) of as-3 is transferred into one rbc collection bag when using the rbcp protocol or 2 separate bags when using the 2rbc protocol. as-3 solution provides nutrients to keep the red blood cells viable for 42 days when refrigerated. cp2d is also indicated for the collection of ffp and pf24 plasma, collected and stored plasma collected using the 822, 822-2p and 822f-2p disposable sets may be frozen within 8 hours